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Sickle cell disease (SCD) is the most common severe genetic disease. It 
impacts approximately 7,000 people in California and nearly 90,000 in the 
U.S. And yet remarkably little is known about the population impacted by 
SCD as a whole. Only recently has this disease become part of the nation’s 
public health agenda. Estimates of the prevalence of disease are not based 
on patient counts but rather on extrapolations of newborn screening 
data using data on life expectancy (itself extrapolated from other data) or 
based on patient counts from hospital discharge databases. While much is 
known of the pathophysiology of the disease, little is understood about the 
impact of the disease on people, particularly adults, living with SCD. 
Estimates of the incidence of disease are not based 
on patient counts but rather on extrapolations of 
newborn screening data with life expectancy. 
The Sickle Cell Disease Longitudinal Data Collection project in California 
extends over five years of successful SCD surveillance in the state as part of 
the Center for Disease Control and Prevention’s (CDC) and National Heart, 
Lung and Blood Institute’s Registry and Surveillance System in Hemoglo-
binopathies (RuSH) and CDC’s Public Health, Research, Epidemiology and 
Surveillance in Hemoglobinopathies (PHRESH) cooperative agreements. 
The goals of this new effort are to continue using and to improve upon 
developed methods and data sources for understanding SCD at the pop-
ulation level in the state as well as to analyze the data collected and dis-
seminate them to audiences that will drive policy and health care chang-
es, leading to improvements in quality of life, life expectancy and health 
among those living with SCD. 
Data sources for this surveillance system include administrative data 
(hospital discharge data, emergency department data, and Medicaid 
claims), newborn screening case reports, vital records and eventually clin-
ical case reports. These data will be linked, de-duplicated and condensed 
to form a profile of the health conditions, health care and outcomes of this 
population. 
After meetings with over 20 stakeholder groups in California and at the 
federal level, the suggested topics for analysis and dissemination using 
these data are as follows: 
• Geography of patient population 
• Transition from pediatric to adult care 
• Hispanic SCD cases 
• The aging SCD population 
• High health care utilization patterns among SCD patients 
This report describes in detail these and other potential topics and pro-
vides a plan for accomplishing these goals. 
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Sickle cell disease comprises multiple genotypes that manifest in signifi-
cant disease severity, such as hemoglobin (Hb) S/S and Hb S/β0, generally 
more severe, and Hb S/C, Hb S/β+ and other Hb S sub-types that typically 
manifest as less severe forms of the disease. It is estimated to affect 90,000 
in the US1. SCD was once thought of as a childhood disease with the ma-
jority of cases dying before adulthood, but the screening of newborns and 
subsequent use of prophylactic penicillin in identified cases and imple-
mentation of comprehensive care models in the late 20th century dramat-
ically changed the life expectancy and disease course for those with SCD2,3. 
Recent estimates suggest that mortality rates among young children with 
SCD are not significantly different than the general population, and over 
95% of SCD cases born today will live into adulthood2,4. 
This change in age distribution for the population living with SCD is 
welcome, but comes at a price. SCD is now a chronic, debilitating, com-
plex, life-threatening disease with its primary impact on adolescents and 
adults5. Rates of emergency room and hospital utilization are high among 
adults with this disease6. For adults, use of the excellent comprehensive 
care models developed for the pediatric population is low due to a variety 
In California, there are fewer than five hematolo-
gists seeing adult SCD patients. 
of challenges including lack of availability of care, lack of insurance, and 
the distance or lack of transportation to care. In California, as in the rest 
of the nation, there are few hematologists trained and willing to care for 
adult SCD patients; much of the care of these patients takes place in emer-
gency rooms or other non-specialty settings7,8. 
Among children, primary severe complications of SCD include anemia, 
septicemia or other severe infection (limited by use of penicillin), stroke, 
splenomegaly or splenic infarction, acute chest syndrome and debilitating 
acute pain9,10. Among adults, pain (both severe acute pain episodes called 
‘crises’ and chronic pain) is the hallmark of the disease. Avascular necrosis 
in the large joints (hip, shoulder), stroke, and organ damage particularly in 
the kidneys and heart are among the primary causes of healthcare utiliza-
tion by adults6,9,10. A recent study of mortality among the SCD population in 
California and Georgia reported a median age of death of 43 years, signifi-
cantly lower than that of the general populations of those states4. 
Beyond prophylactic penicillin for children up to age five, treatments for 
this disease are limited. Bone marrow transplant carries significant risks 
of severe complications or death, but has become lower risk as technology 
has improved. However, candidates must meet eligibility criteria and have 
a suitable match. Some patients with severe disease require regular blood 
transfusion to prevent stroke and other complications; this procedure also 
carries significant risks (e.g., fluid overload, iron overload, disease expo-
sure, and antibody formation) and is time-intensive for the patient11. Hy-
droxyurea is a drug developed as a chemotherapeutic agent and approved 
for use in the adult Hb S/S and S/β0 populations in 1998. It has been 
shown to raise the body’s production of Hb F (fetal hemoglobin), which 
reduces the proportion of Hb S in the blood stream and lowers the rate of 
complications such as pain and acute chest syndrome as well as the need 
for blood transfusion among approximately 75% of study patients. Uptake 
of hydroxyurea is low for a number of reasons, including patient and pro-
vider reluctance to chronically use a drug with a ‘black box’ warning12-16. 
The landscape of care and treatment for those with SCD is poised to 
change dramatically, however. Pharmaceutical companies are currently 
testing at least 39 compounds in clinical trials for SCD or for conditions 
that impact those with SCD. The SCD community has high expectations 
that these treatments will lead to improved life expectancy, lower health-
care costs and higher quality of life for this population17,18. The compounds
have diverse roles and a variety of expected endpoints. They include those 
that increase production of Hb F, target oxidative injuries and inflamma-
tion, or reduce cell adhesion among sickled cells. As these treatments 
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move into Phase III and IV clinical trials and wider usage, a challenge will 
be determining effectiveness vs. efficacy, uptake at the population level, 
the impact on health care utilization, and changes in outcomes due to the 
compounds. While life expectancy and descriptions of complications and 
health care utilization among those with SCD have been documented in 
small clinical populations, there have been only limited studies published 
using population-level data for SCD. 
The SCD Longitudinal Data Collection System (SCD LDC) proposes to 
collect, synthesize and disseminate multi-source, population-based data 
collected over time that will establish a baseline health profile of the SCD 
population prior to the introduction of new therapies. It will then track 
changes in population outcomes over time. A longitudinal data system will 
ensure that the SCD community has credible, scientifically sound informa-
tion to inform standards of care regarding these novel treatments. 
The landscape of care and treatment for those 
with SCD is poised to change dramatically. 
Sickle Cell Disease Surveillance in California 
California began universal newborn screening for all forms of SCD in 
199019. Approximately 133 cases of SCD (including all genotypes) are 
identified per year among approximately 500,000 births20. The California 
Department of Public Health (CDPH) follows up on each case after birth 
to assure that the child has been seen by a pediatric hematologist. These 
providers offer parent education and, most importantly, prescribe prophy-
lactic penicillin to be used for the prevention of severe infections. In 2011, 
the state implemented a ‘long-term follow up’ program that further tracks 
these children annually over the first five years of life, assuring that they 
are in regular care, continuing on penicillin, and tracking any complica-
tions or other health events. The state does not track children with SCD 
after age five21. 
There are numerous hospital-based pediatric clinics for SCD and oth-
er genetic childhood disorders in California22. Most of these have some 
form of internal clinical database for tracking patient care and outcomes 
over time23. Some of these clinics also see adult patients, especially during 
young adulthood/transition23. Typically, patient care that occurs outside 
of their system is not recorded in the SCD clinics’ electronic health records 
systems, including care that may not be directly related to SCD, such as 
for injuries or malignancies, or for illness that may be secondary to SCD 
such as renal disease and heart disease. Data collected by clinics in local 
databases or electronic health records belong to the clinic (and patients), 
and clinicians may or may not disseminate analyses of these data. It is also 
clear that in California, a substantial portion of adult patients are not seen 
in clinical settings nor are they included in data from these sites24. 
Researchers in California and other states have conducted state level or 
sub-state level surveillance of SCD using administrative data, such as hos-
pital discharge data or large commercial claims databases25-28. These ef-
forts are closer to population-based surveillance and less biased than data 
from SCD clinics, as they do not rely on a clinical population and include 
health care utilization over the life course, but they have significant biases.
Research suggests that analyses such as these may dramatically overesti-
mate the number of cases (by including patients who have coding errors 
or ‘rule out’ diagnostic codes) and underestimate the utilization by true 
cases (by not including utilization that does not specifically include SCD 
diagnostic codes)27. Preliminary results with California and Georgia data 
(described below) show similar findings for death records, which suggests 
that these data alone are not a reliable source for determining SCD preva-
lence or life expectancy4. 
California was one of seven states that developed and systematically 
tested a multi-source surveillance system by participating in a coopera-
tive agreement with the Centers for Disease Control and Prevention (CDC) 
and the National Heart, Lung and Blood Institute (part of the National In-
stitutes of Health) called the Registry and Surveillance System for Hemo-
globinopathies (RuSH, 2010-2012)29. All states that participated in RuSH 
agreed to collect data on the same populations, outcomes, complications, 
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and treatments at the state level; the methodology and data sources dif-
fered across states. California used data from the following sources: 
•	 Newborn screening (SCD case identification 2000-2008) 
•	 Hospital discharge data (all data 2004-2008, since expanded through 
2013) 
•	 Emergency room data (all data 2005-2008, 2004 was not available, data 
since expanded through 2013) 
•	 Medicaid claims data for all patients with one or more SCD ICD diagnos-
tic codes (2004-2008) 
•	 Vital records (all deaths 2004-2008; births linked to SCD cases 2000-
2008) 
•	 Clinical case reports from two large SCD treatment centers (2004-2008) 
California RuSH staff cleaned and standardized these data and devel-
oped a linking algorithm to create a profile by case across multiple data 
sources. For example, a child identified in newborn screening and linked 
to a birth certificate might also be seen among the cases reported by one 
of the care centers, appear in the hospital discharge data as having one or 
more emergency room visits or inpatient stays, and might have Medicaid 
utilization data. This child would be counted as an incident case only once, 
but her profile would include information from all of these sources. As a 
final step, a RuSH case definition was applied to describe the certainty of 
the evidence that each case had SCD: confirmed, probable or possible. 
California was one of two states (along with Georgia) that performed 
validation and improvement work on the RuSH data in a subsequent co-
operative agreement with the CDC called Public Health, Research, Epide-
miology and Surveillance in Hemoglobinopathies (PHRESH, 2012-2014). 
During the PHRESH validation project, California refined its case defini-
tion and improved its linking and matching methods using the RuSH data-
set and additional confirmed case reports from six comprehensive hemo-
globinopathy centers in the state30. 
Key Surveillance Findings from the California RuSH 
and PHRESH Projects 
The data from these projects led to surprising conclusions about the 
SCD population in the state. Among the published and in-development 
analyses is evidence of the importance of a broad-based, population-level 
surveillance effort for this disease. 
• Clinical data sources are inadequate for tracking adult SCD cases; 
among the five largest hemoglobinopathy centers in California that see 
some adult SCD patients, a total of 492 adult patients were reported. 
However, estimates from the PHRESH project suggest there should be 
approximately 3,000 adult SCD patients in the state 
•	 43% of confirmed and probable SCD cases who died during the 2004-
2008 period and were linked to a death certificate did not have SCD or 
51% of the state’s confirmed and probable adult 
SCD cases live in Los Angeles County, which no 
longer has an adult SCD clinic. 
a condition linked to SCD listed among their causes of death 
• Preliminary results (not yet published) suggest  the following: 
◊ Patterns of high utilization are not consistent within a patient over 
time; patients are high utilizers (of emergency and inpatient services) 
for a period of some months, then return to expected levels of health 
care use 
◊ Older patients (over 40 years) have different health care utilization 
patterns than younger adult patients, with more visits coded for other 
health care problems related to organ failure (such as end stage renal 
disease) and other morbidities of older adults (diabetes, cancer, heart 
disease), rather than SCD 
◊ 51% of the state’s confirmed and probable adult SCD cases live in Los 
Angeles County, which no longer has an adult SCD clinic 24. 









Other Current SCD Data Collection Efforts 
The importance of data collection for the understanding of treatments, 
outcomes and access to care among those with SCD is well known. In ad-
dition to efforts described above (newborn screening, clinical databases), 
there are other projects proposing to collect data on people living with 
SCD. The similarities and differences among these programs in states par-
ticipating in the SCD LDC should be clearly understood. 
Health Resources and Services Administration (HRSA)/Sick-
le Cell Disease Association of America (SCDAA) GetConnected
Project 
SCDAA Press Release: 
http://sicklecelldisease.org/index.cfm?page=news&id=85 
One component of this HRSA grant awarded to SCDAA is a voluntary pa-
tient registry that will require patient consent to join, will focus on collect-
ing data on access and quality of care among those patients engaged with 
SCD community-based organizations, and will enable communication to 
patients about educational and clinical opportunities and information 
National Heart, Lung and Blood Institute Sickle Cell Disease
Implementation Consortium (SCDIC) RFA-HL-16-010 
NIH Funding Opportunity Announcement: 
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-010.html 
This upcoming award will include an extensive data collection effort 
among awardee patient populations. This project will collect data on pa-
tients 15 to 45 years of age who are identified, recruited and consented at 
clinical sites. 
California’s SCD Longitudinal Data Collection System 
With new funding, California plans to continue and expand its well-de-
veloped and broad based SCD surveillance system established through 
participation in the RuSH and PHRESH projects. The new project is now 
located in the California Environmental Health Tracking Program at CDPH, 
in the California Rare Disease Surveillance group (CRDS). This program 
brings with it new areas of expertise in database development and link-
age, geographic/spatial analysis and mapping, data analysis and statistical 
methodology, and outreach and dissemination. There is staff continuity 
in project management and data acquisition for this project, and we have 
excellent documentation for new staff joining us for data linkage and da-
tabase development. All state agencies and clinical partners remain sup-
portive of this work and are planning to continue to contribute data as 
resources are available. As informed by the RuSH and PHRESH projects, 
the new system will do the following: 
•	 Begin with the same administrative and statewide data sources as used 
previously, with data collected through 2013 (additional years as soon 
as available) 
•	 Request case reports from our clinical partners for new cases seen since 
2008 
•	 Use the revised, validated case definition for SCD developed by Califor-
nia during the PHRESH project 
•	 Revise the structure used for linking, matching and analyzing data 
◊ Use a relational database format rather than flat file 
◊ Develop a revised (based on lessons learned) matching and linking 
process 
◊ Review ‘by hand’ cases that are unusual or ‘borderline’ for case defini-
tions, and all newborn screening cases (which are difficult to link due 
to limited consistent personal identifiers) 
◊ Create systems for more agile and flexible data analyses, rather than 
sorting/matching all data for each analysis 
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Goals and Areas of Focus 
Over a two-month period, June-July 2015, California’s SCD LDC project 
management staff held over twenty small group meetings with commu-
nity-based organizations, clinicians, state agency staff, and patients and 
their families throughout the state, as well as with federal agency partners, 
relevant national association partners, and stakeholders in the Washing-
ton, DC and Baltimore areas. A complete list of the participants in these 
meetings is in Appendix A. The goals of these meetings were the following: 
•	 Inform stakeholders about the project and answer questions 
•	 Enhance or develop collaborative relationships 
•	 Assure continued availability of surveillance data 
•	 Recognize gaps and overlaps in SCD surveillance among different pro-
grams and plan to mitigate 
•	 Determine the most valuable products that could come from this effort, 
taking into account time, available resources and complexity 
Based on the experience of RuSH and PHRESH, we learned that the data 
collected are highly valuable for answering certain types of question (e.g., 
California’s SCD LDC project management staff 
held over twenty small group meetings with 
community-based organizations, clinicians,
state agency staff, and patients and their fami-
lies throughout the state, as well as with feder-
al agency partners, relevant national association 
partners, and stakeholders in the Washington, DC 
and Baltimore areas. 
disease prevalence, health care utilization, clinical outcomes) but not 
helpful for others (quality of life, education and employment status, 
some clinical markers such as units of blood transfused, or compliance 
with oral medications). We also learned that some clinical questions are 
so complex that considerably more data and analysis would be need-
ed to answer them compared to useful but simpler questions that have 
never before been addressed in the literature using population-based 
data. Finally, we know that some areas of investigation are of great in-
terest, but hold low probability of influencing change. We placed a high 
priority on those questions that had a clear path to changes in policy 
or health care practice for patients. With these parameters in mind, we 
encouraged the attendees of the meetings to share their highest priority 
questions of the data. 
We propose here five broad areas of focus based on these conversa-
tions and highlight the reasons for the choices, the specific questions we 
may answer, the literature and background on the topics, and improve-
ments in patient outcomes or quality of care that may result from this 
work. 
Geography of Patient Population 
With nearly 38 million residents and 164,000 square miles, Califor-
nia is larger than many nations; it is the most populous state and the 
third largest in land mass. The state’s population is highly diverse in 
its racial and ethnic makeup, country of birth, languages spoken, and 
socioeconomic status, but sub populations for all of these demographic 
variables are clustered. Our preliminary analyses found that SCD cases 
are clustered in different parts of the state, which has not been previ-
ously described in the literature. Our data offer us a unique opportu-
nity to analyze and present the demography and geography of SCD in 
California. A simple representation of this power is shown in Figure 1, 
which identifies counts of newborn screening identified cases of SCD 
by county. With the proposed surveillance methods, we can also look at 
sub-county data, including city or, in the case of large cities such as Los 
Angeles, neighborhood. These data can also demonstrate the geograph-
ic challenges in gaining access to care. 
 
 
Longitudinal Data Collection for Sickle Cell Disease in California 
Figure 1: California Newborn Screening Identified SCD Births, 2004-2008 
In addition, spatial disease data modeling can be a useful analytical tool, 
if the levels of aggregation (e.g., census block, city, county) are thoughtfully 
selected to best answer the research question31. Although early attempts 
at mapping to explain and intervene in disease patterns met significant 
challenges, recent research has led to improvements in methodology and 
standardization of best practices from which the SCD LDC project can ben-
efit32. 
SCD researchers in the US have explored sociodemographic factors af-
fecting the disease using simple spatial techniques. Clinical studies out-
side of California have found that sociodemographic status based on pa-
tient zip codes was not associated with longer hospital stays or outcomes 
among SCD patients33,34. Other researchers have examined access to care 
via public transit, and the effect of such access on outcomes35. A recent 
California-based study assessed access to care by determining the approx-
imate distance from patient’s home (the distance from the center of the 
patient’s zip code area) to the site of care for patients with SCD ICD 9 codes 
in emergency department data, as well as other socio-demographic fac-
tors associated with SCD hospital utilization and outcomes. It showed that 
Our data offer us a unique opportunity to analyze 
and present the demography and geography of 
SCD in California. 
geographic distance to care and patient insurance status are significant 
predictors of ED utilization36. No other relevant publications describing 
SCD distribution or care as a function of geography in California have been 
identified. 
Specific questions regarding patient location include the following: 
•	 Where in the state (by city or zip code) are patients located? 
•	 What facilities are seeing SCD patients, and in what setting (e.g., county 
hospitals vs. private hospitals, emergency department vs. outpatient 
clinics)? 
◊ Are individual patients being seen in multiple care facilities (e.g., more 
than one ED)? 
◊ Are there nearby hemoglobinopathy treatment centers that may be 
better able to serve these patients? 
•	 Based on these numbers, where are target areas for outreach? 
•	 What are the differences in access to care by distance (proximity to 







◊ How does this differ by patient age and payer? 
•	 How does availability of public transportation impact access to care? 
•	 Can we point patients in need of knowledgeable primary care to specific 
providers based on Medicaid physician data? 
•	 How do environmental factors (housing or socioeconomic status as de-
termined by census data, air quality as determined by local monitor-
ing) impact patient health and outcomes? 
Dissemination of answers to these questions may be via publicly avail-
able report(s) or fact sheets made available to community-based organiza-
tions, policy makers and the general public. Answers to the questions are 
not time dependent, and CRDS has experts in geographic representation of 
health data on staff, so analyses of these data may be available early in the 
analysis and dissemination phase of the work. 
Collecting, analyzing and disseminating such data is a powerful tool for 
identification and mitigation of gaps in services and access to care chal-
lenges, direction of outreach efforts for clinical programs and community- 
based organizations, guidance for legislators seeking to understand the 
public health priorities of their constituents. Publication and sharing of 
data such as these may result in new neighborhood clinics that can ad-
dress the needs of SCD patients, new patient transportation options to 
bring children and adults to existing clinics, outreach drives to connect 
people with SCD with services, targeted workforce development (i.e., re-
cruitment of providers in case-dense areas willing and trained to work 
with this population) and changes in funding of SCD research and treat-
ment driven by legislators in districts that are highly impacted by SCD. 
Transition from Pediatric to Adult Care 
By contrast with the geography of the patient population, much has been 
published on the challenges of patients moving from a comprehensive and 
coordinated pediatric care setting to an adult setting (acknowledging that 
dedicated hemoglobin adult care centers are rare in California), in both 
the general population and in SCD and other chronic inherited diseases. 
SCD is a special case; with widespread use of prophylactic penicillin and 
monitoring for stroke risk in the pediatric population, the period of transi-
tion coincides with the onset of the most severe symptoms and high health 
care utilization for patients in regions with high quality pediatric care6,10,37. 
Teen and young adult patients suffer from more frequent SCD-related 
complications than younger pediatric patients10,37. In particular, pain cri-
ses, chronic pain, and avascular necrosis are frequently seen beginning in 
the later teen years and into adulthood and the frequency of diagnoses 
for SCD complications increases markedly after age 1610. The increase in 
complications, accompanied by a decline in transfusion frequency, is likely 
due in part to a decrease in close medical follow-up and preventive care as 
patients transition to adulthood, and may be in part due to psychosocial 
factors and access to care issues8,38-43. 
Additional studies that analyzed Medicaid and other administrative data 
have documented the increase in the frequency of ED and inpatient and 
outpatient visits post-transition to adulthood8,25,35. While Hemker et al. ex-
amined data from different types of providers, the study primarily focused 
on whether lack of outpatient care during transition leads to increased use 
of the ED rather than on provider usage patterns8. The authors found that 
Teen and young adult patients suffer from more 
frequent SCD-related complications than young-
er pediatric patients. 
increased ED utilization after transition suggests lack of access to primary 
care providers for SCD patients. Andemariam et al. found in a clinical trial 
that longer travel distance to an adult SCD center is a risk factor for an 
unsuccessful transition35. 
Additionally, at least one cohort study has found that shortly following 
the transition to adult medical care, young adults are at high risk for death1. 
Hamideh and Alvarez examined death certificates to find that young adults 
with SCD, 20–24 years of age, were at over double the risk for mortality 
(1.4/100,000 patients) than 15- to 19-year olds (0.6/100,000 patients) 
Page 10 















Few studies have examined conditions in childhood that predict out-
comes after transition. Boyd et al. found in a clinic-based study that asth-
ma is associated with higher mortality rates in SCD patients, but did not 
explore whether childhood asthma specifically predicts poor adult out-
comes45. Platt examined a variety of acute and chronic conditions in adults 
with SCD that were risk factors for early death in patients 20 and older, 
including renal failure, acute stroke and chest syndrome, and pain epi-
sodes46. 
Our stakeholders noted the importance of quantitative data on compli-
cations, outcomes and utilization during the transition period. Specifically, 
areas of interest that mesh well with the planned data include: 
•	 Where are patients seen during the different phases of transition (e.g., 
16-18 years, 19-21, 22-24)? 
◊ Pediatric comprehensive care clinic? 
◊ Primary care physician? 
◊ Adult hematologist? 
◊ Emergency room? 
◊ Primary, secondary or tertiary hospitals? 
•	 What is the age of onset of complications such as acute pain crises, avas-
cular necrosis, and other identified complications? 
•	 Can we determine to what degree increased health care utilization is a 
function of disease vs. lack of care options? 
•	 What conditions in childhood predict poor young adult outcomes? 
◊ Asthma 




•	 What proportion of transition-aged patients die, and what are the caus-
es of death? 
◊ Are there events or diagnoses that predict mortality in this age group? 
Answers to most of these areas of study will require collecting multiple 
years of data (e.g., predicting adult outcomes based on childhood compli-
cations, mortality) and tracking patients over time. These analyses may 
be best conducted once a significant number of years of data have been 
linked. The SCD community has expressed strong interest in the results 
of these analyses. We believe publication of results in peer reviewed jour-
nals will ensure a wide audience. Implications and consequences of such 
disseminated analyses may include informing workforce development ef-
forts to recruit and train more qualified providers for the transitioning and 
adult population, changes in the structure of pediatric hemoglobinopathy 
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clinics to allow for internal transition to in-house adult programs (as has 
been done in some California clinics), increased screening for complica-
tions at specific ages, and better understanding of health care and social 
needs of all of California’s young adults with SCD. 
Hispanic SCD Cases 
People with SCD born in California in 1990 or later were diagnosed at 
birth due to universal newborn screening for SCD, but those born prior 
to 1990 or outside the state (particularly outside the US) may have been 
diagnosed later or may never have been diagnosed at all47. Brousseau et 
al. used SCD newborn screening prevalence rates for Black/African Ameri-
cans and Hispanic/Latinos in conjunction with more recent census data to 
estimate that about 10% of SCD patients in the United States are Hispanic1, 
which may be an underestimate in California due to high immigration of 
Latino populations. Prevalence rates for Hispanic children of non-Mexican 
heritage were almost 30 times higher than for Hispanic children of Mex-
ican ancestry. This may be due to the introduction of the sickle cell trait 
gene from Africa into the Americas through the slave trade, which dispro-
portionately affected the eastern coasts of the US and Brazil, as well as the 
Caribbean47. 
California has a large Latin American population, but Mexican immi-
grants predominate. The RuSH project found that 8% of all SCD patients in 
California were White, Hispanic30. Black Hispanic cases are included under 
the administrative data coding category of ‘Mixed’ and are therefore diffi-
cult to identify as such. The proportion of the Hispanic population living 
with SCD remains low in California, but the increasing proportion of the 
state’s population that is Hispanic and a decreasing Black/African Amer-
ican population (from 6% in 2010 to <5% in 2040) means that a higher 
proportion of SCD cases are non-Black and/or mixed race48. 
Anecdotal reports and one publication suggest that there are challenges 
to diagnosis and treatment among Hispanic and particularly immigrant 
cases, with physicians not screening non-Black patients despite presen-
tation with relevant symptoms49. With the exception of reports on rates 
of Hispanic newborn cases of SCD, there is no published literature on the 
changing race/ethnic makeup of the disease in California to date50. 
In a clinical study, researchers found no difference in baseline and hy-
droxyurea-induced percent fetal hemoglobin, a determinant of SCD dis-
ease severity, in African American and Hispanic patients aged 4 to 21 
years51. No other relevant literature addresses whether conditions, symp-
toms, complications and outcomes differ in SCD patients based on race/
ethnicity. 
Questions raised by our stakeholder groups include the following: 
•	 Number/proportion of California SCD cases by race/ethnicity and age 
•	 Origin of immigrant cases (region, country or state of birth) 
•	 Challenges to diagnosis of cases born outside the country or prior to 
newborn screening (while there is strong interest in this topic, this may 
be outside the scope of the project due to lack of available data) 
•	 Differences in complications, co-morbidities, outcomes, mortality and 
utilization among SCD cases by race/ethnicity. Whether the following 







additional factors are relevant: 
◊ Age 
◊ Payer/insurance status 
◊ Region/access to care 
Because coding of race and ethnicity in administrative and even clin-
ic and newborn screening data can be erratic, this may be a challenging 
topic52. Our stakeholders expressed an urgent need for as much informa-
tion as possible, however. One option for gathering focused information 
on this subpopulation would be to partner with clinics in a region with a 
high prevalence of Hispanic cases (identified using LDC data). This work 
would be funded by other sources. Results of analyses of these data could 
be disseminated to physicians, insurers and policy makers in the state via 
fact sheets and presentations at relevant meetings. Intended consequenc-
es would be a wider and greater understanding among health care pro-
viders of the prevalence of SCD (and sickle cell trait and its implications) 
among the Latino population, increased research into the differences in 
disease pathology and outcomes by ethnicity and race, and increased out-
reach and education about SCD and trait in Hispanic/Latino communities. 
Anecdotal reports and one publication suggest 
that there are challenges to diagnosis and treat-
ment among Hispanic and particularly immi-
grant cases, with physicians not screening non-
Black patients despite presentation with relevant 
symptoms. 
The Aging SCD Population 
Only recently have there been a significant number of SCD cases with 
severe genotypes to study into older age; the widespread use of preven-
tative treatment among the pediatric population has allowed patients to 
live into adulthood2,46,53,54. Consequently, little has been published about 
complications, co-morbidities and health care utilization among cases 
over the age of 45 years. A recent paper by Sandhu and Cohen addressed 
the most common complications and co-morbidities among a clinic-based 
cohort of adult patients in New Jersey55. It found that the majority were 
not undergoing routine screenings for cancers and that a high number had 
important co-morbidities, such as hypertension and diabetes, and early 
onset complications, such as chronic renal disease, iron overload and car-
diovascular disease. 
Previous clinical research has shown that pain crises tend to lessen in 
number and possibly in severity in SCD patients over the age of 40, al-
though not all studies agree on this point56. Sanders et al. compared groups 
of younger adults with SCD (age 18-36) and older adults with SCD (age 37-
62) on pain, complications and health care utilizations57. The study found 
a significant difference only in the patterns of health care utilization; older 
adult patients had more outpatient clinic visits, while younger adults had 
more ED visits and hospital admissions. Serjeant et al. studied a Jamaican 
cohort of surviving patients aged 60 and older with Hb SS. Survival was as-
sociated with clinical features indicating a milder course of the disease58. 
Hamideh and Alvarez analyzed mortality statistics to compare the av-
erage life expectancy among African-Americans with and without SCD in 
200944. Most of the deaths for both groups were attributed to cardiovas-
cular causes; these cardiovascular deaths occurred much earlier in SCD 
patients than in the non-SCD African American population, with a peak in 
the late thirties to early fifties. They found that cancer and diabetes, the 
second and fourth largest causes of death among African-Americans with-
out SCD, were not leading causes among African-American SCD patients. 
Questions on this subject raised by our stakeholder groups include the 
following: 
•	 What are common complications and co-morbidities over age 45 in the 
SCD population? 
•	 Are common diseases of adults (such as cancers, heart disease, diabe-
tes) routinely screened for in this population? Do these diseases occur 
at the same rate as in the general population? At the same mean/me-






•	 How do health care utili-
zation patterns change
from one age group to 
another? 
•	 Whom do older patients 
see for care? Do they see 
specialists for compli-
cations of SCD, such as 
nephrologists for kidney 
disease, cardiologists for 
heart disease? 
•	 How does cause of death 
differ among older and 
younger adults? 
•	 What is the rate of pre-
ventable causes of death 
in SCD compared to that 
of other, similar chronic 
diseases? 
•	 What is the rate of renal disease compared to the general population 
and the Black/African American population? Is age of onset earlier? 
◊ Rates of kidney transplant 
◊ Rates of adverse outcomes 
◊ Autoimmune hemolytic failure 
•	 What is the rate of pain crises, iron overload, leg ulcers and avascular 
necrosis among this older population compared to younger groups? 
As with results of analyses on the transition from pediatric to adult care, 
we believe analyses of these data on the aging SCD population will be in-
formative to a national and international audience. We suggest that peer 
reviewed journals are the best venue for dissemination. These analyses 
will also require as many years of data as possible to accurately portray 
the population in the older ages, as well as capture events or complica-
tions that may be predictive of future outcomes, so we contemplate sched-
uling these analyses for later years of this work. Intended outcomes for 
this work would be increased understanding of the health care utilization, 
clinical outcomes, access to care and support needs of this population, 
outreach efforts to non-hematologist specialists who may be seeing these 
patients for complications, increased ability to identify and follow these 
older patients in administrative data, updated mortality and life expectan-
cy analyses, and improved and expanded standards of care that include 
more information on complications among older SCD patients. 
Little has been published about complications, 
co-morbidities and health care utilization among 
cases over the age of 45 years. 
High Utilization Patterns Among SCD Patients 
By contrast with the other topics, much has been written on high hos-
pital and emergency department (ED) utilization by SCD patients. Most 
analyses are based on limited, clinic-based cohorts or on the use of single 
administrative (hospital discharge or ED) data sets59-64. As noted above, 
these data sources are limited in their capacity to identify confirmed or 
highly probable cases and to look at all utilization, not just ED or inpatient, 
and not just encounters with SCD diagnostic codes included27. 
Brousseau et al. studied administrative data to estimate SCD population 
utilization, finding 29% had no ED visits or hospitalizations while 16.9% 
had 3 or more per year25. That study also found age to be a factor in re-
admissions. Ezenwa et al.’s longitudinal comparative investigation found 
that a SCD patient-reported measurement of pain in outpatient visits is 
a predictor of acute health care utilization in the following year, along 
with age but not gender65. Studies by Carroll have looked at high utiliza-
tion patterns. Her 2009 and 2011 study of administrative data sets found 
that among high utilizers, a period of high utilization could be followed 





by moderate periods that were not likely to reverse66,67. The 2011 study 
found that in California, high utilizers were associated with prior hospital-
izations and previous diagnoses of bone death and renal disease. Carroll 
et al. found in a clinical study that age, disease severity, greater parental 
education, and psychiatric illness are significant factors in high care utili-
zation62. A retrospective cohort study found that care for adolescents dif-
fered between children’s hospitals and general hospitals in terms of rate of 
intubation and length of stay68. 
The SCD LDC data are uniquely able to identify the utilization patterns 
among the majority of cases in California, including hospital, ED and out-
patient, and to look for patterns of utilization over time. Additionally, we 
have the capacity to look at events or complications that precede periods 
of high utilization. Among areas of interest for our stakeholders were the 
following: 
•	 Are the high utilizers of ED and inpatient services the same people over 
long periods of time? 
◊ If not, what are the factors that predict high utilization starting and 
stopping? 
◊ What demographic and other variables predict whether a patient be-
comes a high utilizer? 
•	 Do the rates of ED to admission vary by facility type, region, condition 
or other factors? 
•	 What are the patterns of outpatient care in between ED/hospital stays? 
•	 What factors predict readmissions to inpatient or ED settings? 
•	 Are outcomes predicted by type of facility? 
Along with transition and outcomes among older adults, analyses of 
high utilization would be improved with more years of data, may be help-
ful to other states and countries, and are likely to be of high interest to 
researchers. We suggest that these analyses be informed by as many years 
of data as possible and that peer reviewed journal articles will be an im-
portant mode of dissemination. Among the changes in policy, practice and 
outcomes that may result from this work are a greater understanding of 
the triggers for periods of high utilization as well as prevention strategies. 
It could result in increased education of ED providers on the importance of 
timely and adequate pain relief in vaso-occlusive crises to prevent re-ad-
missions and of post ED follow up, and to workforce development efforts 
such that there are enough knowledgeable and trained providers to ensure 
adequate access for SCD patients to outpatient and preventative services. 
Other Suggested Surveillance Topics of Interest 
Our stakeholder groups raised the above focus areas often.  We feel anal-
ysis and dissemination on these areas are achievable within the scope of 
the planned data collection and are likely to have high impact on policy, 
clinical practice or other factors that drive patient outcomes. Many oth-
er areas of interest were also raised in these conversations; some may be 
candidates for additional analyses, while others may require collection of 
different data to address or other resources that are outside the scope of 
this surveillance effort.  Some of these areas of interest are discussed be-
low. 
Health Care Quality for SCD in California 
Stakeholders familiar with care patterns among those with SCD were 
concerned about systemic problems with care at the state level. Differenc-
es in access to care based on payer were cited above all else. Although 
no publications describe the situation specifically in California, stakehold-
ers in our meetings described that the situation is similar to other states: 
adults with SCD who are on Medicaid have few or no physicians who will 
see them due to low reimbursement rates, physician unwillingness to 
manage patients with a highly complex disease, or physician unwilling-
ness to prescribe opioids/narcotics to meet standards of care8,69. The is-
sue of specific challenges with enrollment in the state’s Genetically Hand-
icapped Persons Program (GHPP), which pays for services and treatments 
not covered by Medicaid or private insurers, was raised frequently (RuSH 
data suggested that fewer than 10% of those who qualify enroll). People 
living with SCD and clinical SCD experts alike pointed to the inherent and 
systemic discrimination and bias against those with SCD in the health care 
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system and wondered how to quantify it. Their primary questions were as 
follows: 
•	 How do treatments and outcomes differ by payer? 
•	 What is the rate of enrollments for GHPP (state-based payer)? 
•	 How do outcomes for GHPP recipients compare to outcomes for those 
not receiving benefits? 
•	 How do medical reimbursement rates for SCD compare with other com-
plex, chronic diseases (diabetes, cancer)? 
•	 Is there a way to quantify systemic bias/discrimination in the health 
care system? 
•	 Can Consumer Assessment of Healthcare Providers and Systems 
(CAHPS, from the Agency for Healthcare Research and Quality) data 
inform our understanding of health care quality for SCD? 
•	 What is average time spent in emergency department waiting room 
before being seen? How does this compare to other similar diseases? 
Does it differ by facility type or other factors? 
•	 What is the ED ‘left without being seen’ rate for SCD, and how does it 
relate to wait time? 
•	 How will systemic changes in health care and payment structures in 
the Affordable Care Act impact Californians with SCD? Will the shift of 
Medicaid enrollees to managed care plans improve health care for the 
population, or will it present new challenges for access to care? 
Quantifying and addressing these problems is an enormous challenge. 
Some efforts have been made to do this69-73, and more are needed. However 
the SCD LDC has limited data on costs of care outside of Medicaid claims, 
no information on care quality for those in the general population or those 
with chronic illnesses similar to SCD, nor encounter-level variables such as 
emergency department wait time. We feel the answers to these questions 
are best addressed by other means. 
Costs of Care 
As with quality of health care, there was a great deal of interest among 
stakeholders in understanding potential cost savings to insurers if stan-
dards of care were followed by all providers treating SCD, especially those 
treatments and practices that help prevent complications. Some investi-
gation into these questions has taken place74-76. Stakeholder questions in-
cluded the following: 
•	 What are the costs of preventative treatment and cost savings associat-
ed with them? 
•	 Is there a cost savings in treating SCD patients in a day hospital setting 
(for scheduled transfusions as well as management of pain episodes)? 
Such analyses are possible as a part of the SCD LDC using the Medic-
aid claims data for identified SCD cases (for Medicaid-covered claimants 
only); these data include outpatient treatments, screenings, and use of 
preventative drugs, as well as the outcomes of interest. These are complex 
analyses, however.  Such work is best undertaken when a plan for what 
to do with the results of such analyses to best impact policy and practice 
change is in place.  For this reason, this topic is beyond the scope of this 
project for now. 
Narcotic Use and Pain Management 
Appropriate and adequate use of narcotics to treat pain is an import-
ant aspect of care for adolescents and adults with SCD. This is one of the 
most stigmatized and misunderstood areas of disease treatment and man-
agement, however. Many ED providers believe that patients presenting to 
the ED with specific requests for pain management are ‘drug seeking’ and 
many other physicians not familiar with SCD standard protocols express 
an unwillingness to prescribe the appropriate amount of medication to 
treat acute pain crises by SCD standard of care guidelines69,77,78. Stakehold-
ers expressed an urgent need to understand how, where, what, by whom 
and how often pain medications are prescribed for SCD patients, and what 
the outcomes are based on adherence to SCD standards of care and Ameri-
Longitudinal Data Collection for Sickle Cell Disease in California 
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Stakeholders expressed an urgent need to under-
stand how, where, what, by whom and how often 
pain medications are prescribed for SCD patients, 
and what the outcomes are based on adherence 
to SCD standards of care. It is also clear that in 
California, a substantial portion of adult patients 
are not seen in clinical settings nor are they in-
cluded in data from these sites. 
can Pain Society protocols.  Their questions included the following: 
•	 Can we quantify ‘normal’ narcotic use in SCD? 
•	 Is ‘high’ narcotic use correlated with high utilization at a population lev-
el? 
•	 Are narcotics prescribed to meet standards of care for SCD? 
•	 What are challenges to patients of obtaining narcotic treatment in dif-
ferent settings? 
As critical as these questions are to addressing health, quality of life and 
outcomes among those living with SCD, we feel strongly that the resources 
California has been awarded are insufficient to address this issue at this 
time. This is one of the most complex research areas affecting those with 
SCD, and it would be well served by a multi-agency cooperative effort. 
Transfusions 
Stakeholders said it was important to know how many SCD patients re-
ceive transfusions, rates of chronic vs. intermittent transfusion, outcomes 
associated with transfusion, development of antibodies and infection due 
to transfusion, whether standards of care are being followed in determin-
ing whether to transfuse and how blood should be handled, and costs as-
sociated with the procedure compared to costs of the complications pre-
vented. A high proportion of patients will be transfused over their lifetime; 
CA RuSH data suggests that over 70% of those with SCD will receive one 
or more transfusions during a five-year period79. This treatment is critical 
for preventing many of the life-threatening complications of the disease. 
Specific questions raised by SCD stakeholders include the following: 
•	 Are clinical settings adhering to standards of care for transfusion in SCD 
treatment? 
•	 How many patients are chronically transfused? In what setting? How 
often? 
•	 How many patients are intermittently transfused and under what cir-
cumstances? 
•	 How many units do patients receive? How does this differ by circum-
stance (chronic, ED, surgery)? 
•	 How do transfusions impact short- and long-term outcomes? 
•	 What are patient genotype differences in need for transfusion? 
•	 Is it feasible to create a database of antibodies that different blood banks 
and transfusing hospitals can use to avoid antibody-induced transfu-
sion reactions? 
•	 What are the rates and severity of transfusion reactions (e.g., TACO, 
TRALI, hives, exposure to infectious agents) and adverse outcomes? 
As noted in the 2014 California PHRESH Validation Report, identifying 
and understanding transfusions in administrative and claims data proved 
to be more challenging than anticipated24. Transfusions (both straight red 
blood cell and exchange transfusions) are billed differently in diverse set-
tings (day hospital vs. inpatient, for instance), for different procedures/
purposes, and across health care provider and insurance systems. None of 
the available data include number of units transfused during a procedure. 
Few data sources include information on non-life threatening transfusion 
reactions or acute/immediate adverse outcomes. In short, given the data 
we plan to collect, answering the questions stakeholders proposed would 
be challenging. 
In 2014 the CDC awarded funds to a consortium of researchers and state 
agencies in Georgia to investigate many of these issues, with additional 
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funding awarded to sites in California and Florida in late 2015. The SCD 
LDC will work with the California site to support their collection and anal-
yses of data related to transfusions in SCD; we hope to answer some of 
these questions during this effort. 
Quality of Life, Burden of SCD
Chronic illness affects not just the body, but the whole person, family 
and community. Stakeholders hoped we could explore how SCD brings 
Chronic illness affects not just the body, but the 
whole person, family and community. 
challenges to having a productive life. Their questions focused primarily 
on ‘countable’ variables such as the following: 
•	 How do SCD patients’ employment and educational histories and status 
differ from the general public? 
•	 How many days of work or school are missed annually (by age group) 
due to medical care and health related problems among those with SCD 
compared to the general population? 
•	 What is the financial and quality of life burden of these challenges? 
We believe that some data on school (K-12) attendance exists, and we 
are working to identify the data sets and determine whether they are link-
able to LDC data. These data may enable understanding of the effect of SCD 
on school attendance; the other questions, however, are best addressed 
via qualitative methods such as questionnaires. 
Population-Based Surveillance of Preventative Treatments/ 
Screenings and Outcomes 
Researchers typically conduct extensive clinical research before treat-
ments and screenings become standard in clinical settings. The efficacy 
of treatments such as hydroxyurea, prophylactic penicillin and screenings 
such as transcranial Doppler use for stroke risk is well known, therefore. 
Effectiveness in the entire SCD population, however, has not been deter-
mined. The drop in infant and child mortality that followed universal new-
born screening and subsequent wide adoption of penicillin for the first 
five years of life is widely attributed to that practice, but no such clear in-
dications exist for outcomes stemming from the increased use of hydroxy-
urea, specialized vaccinations such as the pneumococcal vaccine, or other 
practices. Stakeholders were interested in the following related questions: 
•	 How has use of hydroxyurea changed over time? At the population (ef-
fectiveness) level, what is the change in outcomes that can be attribut-
ed to its use? 
•	 How has penicillin prescription and adherence changed over time? 
What proportion of the population remains on penicillin after age five, 
and how do outcomes differ compared to those who discontinue at age 
five? 
•	 What proportion of eligible children has had regular transcranial Dop-
pler screenings, and what is the impact on stroke rate in children? 
•	 What proportion of children has had recommended vaccines, and what 
is the impact on health for these children vs. those with SCD who do not 
have all vaccines on time? 
Monitoring of treatments and screenings and their relationship to out-
comes can only take place when data are complete. Pharmacy data and 
outpatient screenings only appear in insurance claims data among our 
data sources, and we do not plan to have claims for sources beyond Med-
icaid (i.e., private insurer claims). This means there is a potential for gaps 
in the record that would distort conclusions based on these data – a child 
may be ineligible for Medicaid insurance for a period of several years, for 
instance, with no record of vaccinations or screenings. Did she have them 
while covered under private insurance, or did she fail to receive them? We 
feel that with the expected data sources, the completeness of these data 
is insufficient for answering these questions. We suggest that collection 
of data from a wider variety of payers would address this problem, but 
is beyond the scope of this project. However, data from the SCD LDC are 
ideal for monitoring the large scale changes in SCD population health over 
time as new treatments become available and as new treatment guidelines 
and health care policies create change. Such changes, including reduced 
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childhood morbidity and a greatly increased life expectancy, came about 
after the introduction of universal newborn screening for SCD and the 
widespread use of prophylactic penicillin for the prevention of childhood 
infection. 
Rates of Complications
Some stakeholders wondered whether there was enough information 
about the prevalence and rates of complications associated with SCD, 
such as stroke, other neurologic complications, and acute chest syn-
drome. Their questions included the following: 
•	 What are rates of pediatric and adult strokes, time to subsequent 
stroke by age and preventative measures taken, and long-term impli-
cations for health? 
•	 Can we describe neurologic complications beyond stroke? 
•	 Acute chest syndrome and pneumonia rates – have these changed over 
time with treatments/standards of care? 
Using single source administrative data sets such as hospital discharge 
data or medical claims data, previous researchers have published exten-
sively on rates of complications among SCD patients. Rates of pediatric 
stroke have been assessed by age10,26,80, as have pulmonary complications 
of SCD, avascular necrosis10, and other common conditions in this popu-
lation. Because data on most of these conditions are found in inpatient 
hospitalization data and most states have complete data in these files, we 
do not believe we can add information substantially different from that 
already published in these areas. 
Fertility and Pregnancy 
Interest in fertility and pregnancy included questions about whether 
adult women with SCD have complications in getting pregnant and having 
healthy babies compared to the general population, whether there were 
threats to the health of mothers with SCD during pregnancy, interven-
tions or settings that improve pregnancy outcomes in SCD, and rates of 
teenage pregnancy among those with SCD. Some of these questions have 
been addressed in clinic-based studies by other researchers81-86. We may 
be able to add to the information on this topic. It is unclear, however, 
how this information would be used to change policy or outcomes for 
people living with SCD. 
Sickle Cell Trait 
There is a high level of interest among some policy makers and the 
general public about describing health problems that may be associ-
ated with sickle cell trait. Linking the approximately 80,000 sickle cell 
trait cases identified to date in California with health care records is 
outside the scope of this project, however. 
Timeline 
The proposed detailed timeline for the California SCD LDC Program 
follows. These plans are subject to the availability of planned sources 
of data, availability of resources and staffing, and changes in plan due 
to emerging and mutually agreed upon areas of interest in SCD sur-
veillance in the state. Examples of such changes include the approval 
of new treatments, policy and practice changes by insurers or other 
changes in patient care. 
Year 1: Design of data collection system 
We intend to use the first year (April 2015-March 2016) of the proj-
ect for information gathering, infrastructure development and plan-
ning for data collection. In the first four months of the project, we met 
with over 20 stakeholder groups to gather information about high pri-
ority goals and objectives for surveillance of SCD at the state level. We 
will continue to work with these stakeholders in group webinar con-
In the first four months of the project, we met 
with over 20 stakeholder groups to gather infor-
mation about high priority goals and objectives 
for surveillance of SCD at the state level. 
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versations on a quarterly basis as well as in small conversations as needed 
for input. 
We have developed the surveillance agenda described here for discus-
sion. We have also begun work on a data collection protocol that will soon 
be submitted to the state’s Committee for the Protection of Human Sub-
jects for clearance to begin data requests. We will follow this clearance by 
initiating a request for data from the state’s Medicaid office, which histori-
cally has been the most challenging and slow when seeking to obtain data. 
This will be followed by data requests from the state’s newborn screening 
program and vital records agency, as well as updates on emergency room 
and hospital discharge data through 2014 when available (CRDS already 
has possession of these data through 2013, pending permission to use for 
this project). Over time, we will request subsequent years of data and will 
also explore and request additional data sources that can fit well within 
the developed infrastructure and add to our knowledge about this popula-
tion. We will further develop the case definitions for SCD validated during 
the PHRESH project. 
Since the beginning of the funding period, we have hired a part-time 
health communications expert to help with external conversations and 
dissemination of data. Our database development has begun, using in-
house staff and expertise. We have identified a data linkage consultant 
with over 10 years of experience linking data such as those we plan to 
collect, and plan to develop a sub-contract to work with him throughout 
Year 2 of the project. Security for the data is already in place through CDPH 
physical and procedural data protection systems. We anticipate that we 
will begin linking and reviewing some data by mid-winter, prior to the end 
of Year One. 
Years 2-4: Implementation of data collection system 
We anticipate that completion of data cleaning and standardization 
across all years of data (2004-2014), linking and de-duplication, applica-
tion of the case definition and checking of anomalous cases, and develop-
ment of the database and query systems will take much of Year Two. This 
process will be closely monitored by the CDC Division of Blood Disorders 
project officer, with interim milestones established. Once the data systems 
have been developed, new data will be incorporated annually (adminis-
trative data) or every six months (newborn screening, Medicaid claims) as 
available, through the remainder of the project. 
With additional funding, we anticipate requesting data from clinical 
sites with which we already have established working relationships. These 
data will also be incorporated into the system, as they were in RuSH and 
PHRESH data. 
Finally, we will remain in regular contact with stakeholders, continuing 
quarterly meetings and other forms of communication. 
Years 3-5: Data analysis and information dissemination 
As the data are processed to become health care and outcome profiles 
for each patient in the state, we will plan for analysis and dissemination. A 
meeting with stakeholders to discuss preliminary results of data analyses 
will be held in Year Three (along with continued quarterly web conference 
meetings). We plan to use the meeting to develop a list of fact sheets, pre-
sentations and publications to be completed. 
Dissemination will proceed as planned and with on-going input from 
stakeholders. In Year Four we will create a description of how we devel-
oped and implemented the data collection and linking systems to inform 
those who wish to replicate this work. It will be refined and completed in 
Year Five. 
We will hold a final meeting with stakeholders in Year Five to plan for 
next steps in SCD surveillance at the state level. 
Years 6 and Beyond: Continued growth and expansion of
surveillance in sickle cell disease 
Community based organizations, national professional organizations, 
researchers, clinicians and members of the affected community continue 
to encourage Congress to devote dedicated funds to sickle cell disease sur-
veillance at the national level. It is our belief that these efforts will be fruit-
ful and that demonstration of the utility and power of a longitudinal data 
collection system for this disorder in California will inform these efforts. 
Longitudinal Data Collection for Sickle Cell Disease in California 
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Beyond California, it is vital that other states also engage in statewide, 
unbiased surveillance of their SCD affected populations. Each state has 
a unique demographic makeup, distinct policies and implementation of 
Medicaid and ACA, medical and research centers, and access to care. Our 
intention is to work closely with other states that have funding to do this 
work to inform all states’ efforts and compare and contrast differences in 
care and outcomes across states. 
Until recent surveillance and health education efforts from the CDC, SCD 
had been seen primarily as an important clinical issue but had not been 
addressed as a public health concern. Although SCD impacts an estimated 
7,000 Californians, little is known about the health status of those living 
with the disease, particularly adults. This longitudinal data collection proj-
ect is intended to follow all patients over time, including those not seen in 
specialty care centers and not identified by newborn screening. The pro-
file of healthcare utilization, complications, demographics and access to 
care created by the collected data over time will allow us to investigate and 
report on key areas of interest, including patient geography and proximity 
to care, healthcare outcomes associated with transition from pediatric to 
adult care, the emerging Hispanic/Latino SCD population, the health sta-
tus of those who live into their 40’s and beyond with SCD, and triggers and 
outcomes for those patients who experience periods of high emergency 
room utilization. 
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Appendix A: SCD LDC June-July 2015 Stakeholder Meetings and Attendees 
•	 American Society of Hematology 
•	 Association of Public Health Laboratories 
•	 Blood Centers of the Pacific/Blood Systems Research Institute 
•	 California Healthcare Foundation 
•	 Center for Inherited Blood Disorders 
•	 Children’s Hospital Los Angeles 
•	 Children’s Hospital Orange County 
•	 Health and Human Services/Office of Minority Health 
•	 Health Resources and Services Administration/Maternal and Child Health Bureau 
•	 Kaiser Permanente Southern California 
•	 The KIS Foundation 
•	 Loma Linda University Medical Center 
•	 National Institutes of Health/National Heart, Lung, and Blood Institute 
•	 National Medical Association 
•	 Northern California Sickle Cell Advisory Council 
•	 Sickle Cell Disease Association of America 
•	 Sickle Cell Disease Foundation of California 
•	 UC Davis Hematology Clinic 
•	 UC Irvine Medical Center 
•	 UCSF Benioff Children’s Hospital Oakland 
•	 Parents of children living with sickle cell disease 
•	 Adults living with sickle cell disease 
•	 Expert on hemophilia Universal Data Collection system 
•	 Los Angeles City Councilman Sponsored Meeting on SCD 
